[Effects of intravenous administration of memantine in parkinsonian patients (author's transl)].
After a preliminary study in 6 parkinsonian patients concerning the effectiveness and tolerance of 1,3-dimethyl-5-aminoadamantane hydrochloride (memantine) an investigation to assess its short-term effects was performed. In an unselected group of 12 parkinsonian patients 40 mg of memantine diluted in 500 ml of laevulose were applied i.v. within 2 h. The patients were examined under standardized conditions before, immediately after and 2, 4 and 24 h, respectively, using a program of physchological tests. The results give evidence for a favourable influence on rigor and tremor in Parkinson's syndrome as well as on motor drive. In comparative studies memantine showed a better tolerance than adamantylaminosulfate. The short-time effects of the drug could be differentiated from placebo and learning effects.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008559:Memantine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos; D013997:Time Factors
D010919:Placebos; D000547:Amantadine; D008559:Memantine
Die Wirkung intravenöser Gaben von Memantin bei Parkinson-Kranken.